Literature DB >> 11020426

Reversal of optic canal stenosis in osteopetrosis after bone marrow transplant.

N C Kerr1, W C Wang, Y Mohadjer, B G Haik, S C Kaste, E M Horwitz.   

Abstract

PURPOSE: To describe a patient with infantile osteopetrosis and optic atrophy secondary to optic canal stenosis who demonstrated optic canal enlargement after bone marrow transplant.
METHODS: Case report. A 3-month-old infant with infantile "malignant" osteopetrosis underwent ophthalmic examination, including visual evoked potentials, electroretinogram, and computed tomography (CT). Bone marrow transplant was performed at 8 months of age.
RESULTS: Examination revealed visual loss and optic atrophy, left eye greater than right eye, secondary to optic canal stenosis. Flash visual evoked potentials revealed a normal waveform in both eyes with increased latency in the left eye. Electroretinogram was normal in both eyes. CT after bone marrow transplant showed enlargement of the optic canals. Vision remains stable 43 months after bone marrow transplant.
CONCLUSIONS: Bone marrow transplant in infantile osteopetrosis may be followed by reversal of optic canal stenosis and preservation of vision.

Entities:  

Mesh:

Year:  2000        PMID: 11020426     DOI: 10.1016/s0002-9394(00)00543-2

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  3 in total

1.  Spontaneous optic nerve compression in the osteopetrotic (op/op) mouse: a novel model of myelination failure.

Authors:  Yoichi Kondo; Jenna M Ramaker; Abigail B Radcliff; Simona Baldassari; Joshua A Mayer; James N Ver Hoeve; Chuan-Li Zhang; Shing-Yan Chiu; Raymond J Colello; Ian D Duncan
Journal:  J Neurosci       Date:  2013-02-20       Impact factor: 6.167

2.  Blindness as the presenting sign of osteopetrosis in a child.

Authors:  Bipasha Mukherjee; Aman Agrawal; Olma Veena Noronha
Journal:  Oman J Ophthalmol       Date:  2022-03-02

3.  An unusual cause of optic atrophy in a child.

Authors:  Nishant Kumar; Anirudh Singh; Rohit Saxena; Vimla Menon; Sanjay Sharma
Journal:  Indian J Ophthalmol       Date:  2014-04       Impact factor: 1.848

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.